The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
As of April 2025 Amgen has a market cap of NZ$251.45 Billion. This makes Amgen the world's 97th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Marketcap | Change |
---|---|---|
2025 | NZ$251.45 B | 0.44% |
2024 | NZ$250.33 B | 2.71% |
2023 | NZ$243.74 B | 10.43% |
2022 | NZ$220.72 B | 18.98% |
2021 | NZ$185.52 B | 0.01% |
2020 | NZ$185.50 B | -12.37% |
2019 | NZ$211.69 B | 15.85% |
2018 | NZ$182.72 B | 2.8% |
2017 | NZ$177.74 B | 13.2% |
2016 | NZ$157.02 B | -12.2% |
2015 | NZ$178.83 B | 15.68% |
2014 | NZ$154.59 B | 47.57% |
2013 | NZ$104.75 B | 32.19% |
2012 | NZ$79.24 B | 9.89% |
2011 | NZ$72.11 B | 8.73% |
2010 | NZ$66.32 B | -14.42% |
2009 | NZ$77.49 B | -25.62% |
2008 | NZ$104.19 B | 58.1% |
2007 | NZ$65.90 B | -41.71% |
2006 | NZ$113.05 B | -19.94% |
2005 | NZ$141.22 B | 24.67% |
2004 | NZ$113.27 B | -7.17% |
2003 | NZ$122.02 B | 2.48% |
2002 | NZ$119.06 B | -16.23% |
2001 | NZ$142.14 B | -5.03% |
2000 | NZ$149.67 B | 27.94% |
1999 | NZ$116.98 B | 131.59% |
1998 | NZ$50.51 B | 109.67% |
1997 | NZ$24.09 B | 18.26% |
1996 | NZ$20.37 B |
On Apr 23rd, 2025 the market cap of Amgen was reported to be: